David C Henderson

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Schizophrenia and comorbid metabolic disorders
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 66:11-20. 2005
  2. doi request reprint Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 159:140-6. 2008
  3. ncbi request reprint Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:789-97. 2006
  4. doi request reprint Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Hum Psychopharmacol 24:225-32. 2009
  5. doi request reprint Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 29:165-9. 2009
  6. ncbi request reprint Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study
    David C Henderson
    Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1116-21. 2005
  7. pmc Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Psychiatr Pract 15:251-61. 2009
  8. doi request reprint Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    J Clin Psychiatry 70:1674-80. 2009
  9. ncbi request reprint Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
    Ann Clin Psychiatry 22:33-42. 2010
  10. ncbi request reprint Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005

Detail Information

Publications61

  1. ncbi request reprint Schizophrenia and comorbid metabolic disorders
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 66:11-20. 2005
    ..With proper awareness and cooperation on the part of the medical community, caregivers, and patients, the detrimental consequences that may result from the metabolic disorders addressed in this article can be at least partially offset...
  2. doi request reprint Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 159:140-6. 2008
    ..Evaluating PTSD in patients with schizophrenia could have important implications from both clinical and research perspectives...
  3. ncbi request reprint Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:789-97. 2006
    ..Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism...
  4. doi request reprint Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Hum Psychopharmacol 24:225-32. 2009
    ....
  5. doi request reprint Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 29:165-9. 2009
    ..087). The addition of aripiprazole to a stable dose of olanzapine was well tolerated and resulted in significant improvements on several outcome measures that predict risk for medical morbidity...
  6. ncbi request reprint Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study
    David C Henderson
    Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1116-21. 2005
    ..The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease...
  7. pmc Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Psychiatr Pract 15:251-61. 2009
    ....
  8. doi request reprint Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    J Clin Psychiatry 70:1674-80. 2009
    ..Clozapine-induced sedation can worsen cognition and impair social and occupational functioning...
  9. ncbi request reprint Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
    Ann Clin Psychiatry 22:33-42. 2010
    ..The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia...
  10. ncbi request reprint Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005
    ....
  11. ncbi request reprint A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
    J Clin Psychopharmacol 27:380-6. 2007
    ....
  12. doi request reprint Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 118:211-7. 2010
    ..The present study examined whether white blood cell count (WBC), a marker of systemic inflammation, is associated with metabolic syndrome and psychiatric symptoms in non-diabetic patients with schizophrenia...
  13. pmc A placebo-controlled study of sildenafil effects on cognition in schizophrenia
    Donald C Goff
    Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
    Psychopharmacology (Berl) 202:411-7. 2009
    ..In addition, neuronal nitric oxide synthase, another component of the NMDA/nitric oxide/cGMP intracellular pathway, has been reported to be dysregulated in schizophrenia patients...
  14. doi request reprint Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, 25 Staniford Street, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 130:53-6. 2011
    ..Modafinil has been proposed as a treatment for clozapine-induced sedation and metabolic abnormalities...
  15. ncbi request reprint A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005
    ..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation...
  16. ncbi request reprint Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:1372-7. 2006
    ..This study examined the relationship between fasting serum insulin level and resting energy expenditure (REE) in a cross-sectional sample of nondiabetic schizophrenia patients...
  17. ncbi request reprint A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    David C Henderson
    Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
    Am J Psychiatry 162:954-62. 2005
    ..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder...
  18. ncbi request reprint Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics
    David C Henderson
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA
    J Clin Psychiatry 68:533-41. 2007
    ..0-295.9; referred to as "schizophrenia patients" hereafter) treated with atypical antipsychotic agents...
  19. ncbi request reprint Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
    ..Psychiatrists should address this problem by adopting established strategies for prevention and intervention...
  20. ncbi request reprint Prolactin-related and metabolic adverse effects of atypical antipsychotic agents
    David C Henderson
    Department of Psychiatry, Harvard Medical School, and Schizophrenia, Diabetes, and Weight Reduction Research Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 69:32-44. 2008
    ....
  21. doi request reprint Open-label pilot study on vitamin D₃ supplementation for antipsychotic-associated metabolic anomalies
    Neelam Thakurathi
    Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 28:275-82. 2013
    ....
  22. ncbi request reprint Dietary intake profile of patients with schizophrenia
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA, USA
    Ann Clin Psychiatry 18:99-105. 2006
    ..We performed a cross-sectional study evaluating the dietary intake of patients with schizophrenia or schizoaffective disorder treated with atypical antipsychotic agents...
  23. doi request reprint No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 31:231-4. 2011
    ..Whereas efficacy for cognition has not yet been established for any pharmacologic strategy in schizophrenia, an accumulating body of evidence suggests a possible beneficial role of insulin...
  24. doi request reprint Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia
    Joshua L Roffman
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Am J Med Genet B Neuropsychiatr Genet 147:990-5. 2008
    ..It is plausible that cumulative effects of the MTHFR T and COMT Val alleles on intracellular methylation profiles and prefrontal dopamine transmission underlie their interactive effect on perseverative errors...
  25. ncbi request reprint Sexual functioning, psychopathology and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 94:119-27. 2007
    ..The present study was to characterize relationships among sexual functioning, schizophrenia symptoms and quality of life measures. In addition, sexual functioning was compared among patients treated with different antipsychotic agents...
  26. ncbi request reprint Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 63:42-8. 2008
    ..We examined whether the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C functional polymorphisms contribute to negative symptoms...
  27. ncbi request reprint Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Psychiatry Res 149:267-71. 2007
    ..An inflammatory process, as reflected by elevated serum levels of CRP, might be associated with more severe psychopathology in a subgroup of patients with schizophrenia...
  28. pmc Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia
    Christina P C Borba
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 31:653-8. 2011
    ..We now report a randomized placebo-controlled pilot study to examine the effects of ramelteon on obesity and metabolic disturbances among subjects with schizophrenia...
  29. ncbi request reprint Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Arch Gen Psychiatry 62:19-28. 2005
    ....
  30. ncbi request reprint A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  31. doi request reprint Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 72:806-12. 2011
    ....
  32. ncbi request reprint Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 92:90-4. 2007
    ..Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials...
  33. ncbi request reprint Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, the Division of Infectious Diseases and Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 48:405-11. 2007
    ..However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment...
  34. ncbi request reprint Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    Ann Clin Psychiatry 17:95-7. 2005
    ..We report a case of weight loss associated with modafinil-initiation in a clozapine-treated man with schizoaffective disorder...
  35. ncbi request reprint Treatment of cardiac risk factors among patients with schizophrenia and diabetes
    Anthony P Weiss
    Department of Psychiatry, Massachusetts General Hospital, Boston, 02114, USA
    Psychiatr Serv 57:1145-52. 2006
    ..The appropriateness and effectiveness of the outpatient medical management of cardiac risk factors for patients with diabetes who had a diagnosis of schizophrenia or a related psychotic syndrome were examined...
  36. doi request reprint Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation
    Oliver Freudenreich
    Dept of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Acad Psychiatry 37:27-30. 2013
    ..This matters because clozapine is an important evidence-based treatment for refractory schizophrenia that remains underutilized in clinical practice...
  37. ncbi request reprint Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    MGH Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    Psychopharmacology (Berl) 181:358-63. 2005
    ..Schizophrenia is a disorder with cognitive deficits that could stem from cholinergic dysfunction...
  38. pmc Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)
    Oliver Freudenreich
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    Psychiatry Res 176:99-102. 2010
    ....
  39. doi request reprint Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia
    Neelam Thakurathi
    Massachusetts General Hospital, Schizophrenia Clinical and Research Program, Boston, MA, USA
    Expert Opin Investig Drugs 22:259-65. 2013
    ..Discovering new drugs that can improve impaired cognition, thus, is an attractive treatment target for patients with schizophrenia...
  40. doi request reprint Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic
    Ilse R Wiechers
    Dept of Psychiatry, Massachusetts General Hospital, Boston, USA
    Acad Psychiatry 36:118-21. 2012
    ....
  41. ncbi request reprint Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Schizophr Res 86:30-5. 2006
    ..This study was undertaken to examine whether fasting serum insulin levels are associated with the psychopathology profile in a cross-sectional sample of acutely ill non-diabetic inpatients with schizophrenia...
  42. ncbi request reprint Managing weight gain and metabolic issues in patients treated with atypical antipsychotics
    David C Henderson
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Mass, USA
    J Clin Psychiatry 69:e04. 2008
    ....
  43. ncbi request reprint Weight gain with atypical antipsychotics: evidence and insights
    David C Henderson
    Department of Psychiatry, Harvard Medical School, Boston, USA
    J Clin Psychiatry 68:18-26. 2007
    ..Additionally, the need to closely monitor patients' lifestyles and homeostatic components in order to prevent weight gain or facilitate weight loss is emphasized...
  44. ncbi request reprint Inflammation and schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetss General Hospital, Boston, MA, USA
    Expert Rev Neurother 7:789-96. 2007
    ....
  45. ncbi request reprint An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics
    Brenda Vincenzi
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Ann Clin Psychiatry 25:141-8. 2013
    ..We present a retrospective study examining response to treatment with fibrates or statins in schizophrenia patients...
  46. ncbi request reprint Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
    ....
  47. ncbi request reprint Sibutramine: current status as an anti-obesity drug and its future perspectives
    Bikash Sharma
    Massachusetts General Hospital, Schizophrenia Program, Harvard Medical School, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    Expert Opin Pharmacother 9:2161-73. 2008
    ..Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavioral therapy...
  48. ncbi request reprint Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Schizophr Res 92:181-8. 2007
    ..This study examined whether schizophrenia patients homozygous for the risk allele (T/T) exhibit greater impairment in executive function, and determined the extent to which MTHFR's effects on negative symptoms underlie this relationship...
  49. ncbi request reprint Considerations for inpatient versus outpatient treatment with antipsychotics
    David C Henderson
    Harvard Medical School, Boston, Massachusetts, USA
    CNS Spectr 12:3-5. 2007
  50. ncbi request reprint Clozapine and hypertension: a chart review of 82 patients
    David C Henderson
    Department of Psychiatry, Harvard Medical School and the MGH Biostatistics Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Clin Psychiatry 65:686-9. 2004
    ..In this retrospective chart review study, we examine changes in systolic and diastolic blood pressure and treatment for hypertension in clozapine-treated patients...
  51. ncbi request reprint Schizophrenia and diabetes
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Int Rev Neurobiol 51:481-501. 2002
  52. doi request reprint Cancer care for individuals with schizophrenia
    Kelly E Irwin
    Massachusetts General Hospital Cancer Center, Center for Psychiatric Oncology and Behavioral Sciences, Boston, Massachusetts Massachusetts General Hospital Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts
    Cancer 120:323-34. 2014
    ..Despite significant challenges, with collaboration between oncology and mental health teams, individuals with schizophrenia can receive high-quality cancer care...
  53. pmc Capacity building in global mental health: professional training
    Gregory L Fricchione
    Harvard Medical School and Pierce Global Division, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    Harv Rev Psychiatry 20:47-57. 2012
    ..In sum, this article discusses human capacity building in global mental health, provides recommendations for training, and offers examples of recent initiatives...
  54. ncbi request reprint Building primary care practitioners' attitudes and confidence in mental health skills in a post-conflict society: a Cambodian example
    David C Henderson
    Harvard Program in Refugee Trauma at Massachusetts General Hospital, Boston, Massachusetts 02138, USA
    J Nerv Ment Dis 193:551-9. 2005
    ..05). Only confidence in prescribing psychotropic medications improved from posttraining to 2-year follow-up. This study supports the feasibility of training PCPs in a culturally effective manner in a postconflict society...
  55. ncbi request reprint Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents
    David C Henderson
    Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    Curr Diab Rep 2:135-40. 2002
    ..A review of the recent literature and an approach to the evaluation of risk factors to aide in the safe use of atypical antipsychotic agents in presented...
  56. ncbi request reprint Low-dose clozapine and diabetic ketoacidosis
    Jennifer M Lafayette
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychosomatics 44:249-52. 2003
  57. ncbi request reprint Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychiatry 65:307-11; quiz 452-3. 2004
    ....
  58. ncbi request reprint Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?
    David C Henderson
    Psychotic Disorders and Schizophrenia Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    CNS Drugs 16:77-89. 2002
    ....
  59. ncbi request reprint Psychiatric effects of traumatic brain injury events in Cambodian survivors of mass violence
    Richard F Mollica
    Harvard Program in Refugee Trauma, Massachusetts General Hospital, Harvard Medical School, 22 Putnam Street, Cambridge, MA 02138, USA
    Br J Psychiatry 181:339-47. 2002
    ..The prevalence of brain injury and its effects in populations exposed to war violence has not been studied in recent years...
  60. ncbi request reprint Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight
    Oliver Freudenreich
    MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:1372-6. 2004
    ....
  61. ncbi request reprint Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004